Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis? PDF Print E-mail
Thursday, 22 December 2011 20:15
Eric Hachulla, MD, PhD; David Launay, MD, PhD; Luc Mouthon, MD, PhD; Olivier Sitbon, MD, PhD; Alice Berezne, MD; Loïc Guillevin, MD; Pierre-Yves Hatron, MD; Ge´rald Simonneau, MD; Pierre Clerson, MD; and Marc Humbert, MD, PhD;

Pulmonary arterial hypertension (PAH) is a frequent complication in patients with systemic sclerosis (SSc) that has a prevalence of 8 to 12%. Within the last 2 decades, pulmonary fibrosis and PAH have become the leading causes of death in SSc patients. The estimated 3-year survival rate among patients with PAH associated with SSc is approximately 50%. The development of PAH in patients with SSc must be differentiated from that of pulmonary hypertension (PH) associated with severe pulmonary fibrosis. The latter may manifest as a significant reduction of lung volume (FVC 60% predicted and/or total lung capacity [TLC] 60%) and a modest elevation in mean pulmonary artery pressure (mPAP) of 35 mm Hg at rest.

Unlike pulmonary fibrosis, PAH is understood to occur late in the natural course of SSc and more frequently in patients with limited cutaneous SSc (lcSSc). This assertion, however, may benefit from reappraisal. Studies have shown that PAH may be similarly prevalent among patients with diffuse cutaneous SSc (dcSSc) as it is among patients with lcSSc. Robust data estimating the typical duration between the diagnosis of SSc and the diagnosis of PAH are lacking. The aim of this study was to analyze this duration and evaluate the potential relevance of “time of occurrence of PAH” in the course of SSc as a prognostic factor.

Download the full research paper from the link provided below.

 
More articles :

» Thank You

The Scleroderma Care Foundation launched its one month ago on September 1st, and we did so with several aims in mind. Firstly we sought to provide patients, their families, and friends with relevant and timely information on Scleroderma, tips for...

» Mechanism ID’d for Benefit of Stem Cells in Autoimmunity

Bone marrow mesenchymal stem cells (BMMSCs) activate a mechanism involving coupling of FAS/FAS ligand to induce T cell apoptosis and immune tolerance, according to an experimental study published online April 26 in Cell Stem Cell.To investigate the...

» Targeting Systemic Sclerosis: From Bioinformatics to Clinical Research

Systemic sclerosis (SSc), also known as Scleroderma, is a rare autoimmune connective tissue disorder that's difficult to treat. However, thanks to new research at Dartmouth's Geisel School of Medicine and Northwestern University's Feinberg School of...

» Insights on Autoimmune Diseases and their Impact on Women

In a recent press release by the , Dr. Vivian Pinn discussed the latest research on autoimmune diseases in two podcasts with Dr. Robert Carter. Your body's immune system protects you from disease and infection. But if you have an autoimmune disease,...

» Active Biotech Presents Data regarding the 57-57 Project at EULAR

Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data from an exploratory clinical trial in Systemic Lupus Erythematosus (SLE) patients at the Annual European Congress of Rheumatology EULAR 2011, an international event for specialists in the...

» Development of a Five-Year Mortality Model in Systemic Sclerosis Patients

L. Beretta, A. Santaniello, F. Cappiello, N.V. Chawla, M.C. Vonk, P.E. Carreira, Y. Allanore, D.A. Popa-Diaconu, M. Cossu, F. Bertolotti, G. Ferraccioli, A. Mazzone, R. ScorzaReceived on November 17, 2009; accepted in revised form on October 5,...